These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 16164659

  • 21. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis.
    Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T, Takishita S.
    Clin Exp Nephrol; 2004 Mar; 8(1):54-8. PubMed ID: 15067517
    [Abstract] [Full Text] [Related]

  • 22. How long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysis?
    Bellasi A, Kooienga L, Block GA, Veledar E, Spiegel DM, Raggi P.
    J Nephrol; 2009 Mar; 22(2):255-62. PubMed ID: 19384844
    [Abstract] [Full Text] [Related]

  • 23. Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients.
    Zhang Q, Li M, Lu Y, Li H, Gu Y, Hao C, Chen J.
    Nephron Clin Pract; 2010 Mar; 115(4):c259-67. PubMed ID: 20424476
    [Abstract] [Full Text] [Related]

  • 24. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.
    Huybrechts KF, Caro JJ, Wilson DA, O'Brien JA.
    Value Health; 2005 Mar; 8(5):549-61. PubMed ID: 16176493
    [Abstract] [Full Text] [Related]

  • 25. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F, Shamekhi F, Lessan-Pezeshki M, Khatami MR.
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [Abstract] [Full Text] [Related]

  • 26. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study.
    Lemos MM, Watanabe R, Carvalho AB, Jancikic AD, Sanches FM, Christofalo DM, Draibe SA, Canziani ME.
    Clin Nephrol; 2013 Jul; 80(1):1-8. PubMed ID: 23442255
    [Abstract] [Full Text] [Related]

  • 27. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB, Smeeding JE, Brook RA.
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [Abstract] [Full Text] [Related]

  • 28. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM.
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 30. New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials.
    Wang C, Liu X, Zhou Y, Li S, Chen Y, Wang Y, Lou T.
    PLoS One; 2015 Jun; 10(7):e0133938. PubMed ID: 26230677
    [Abstract] [Full Text] [Related]

  • 31. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients.
    Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD.
    Am J Nephrol; 2003 Jun; 23(5):307-14. PubMed ID: 12915774
    [Abstract] [Full Text] [Related]

  • 32. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
    Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J, ADVANCE Study Group.
    Nephrol Dial Transplant; 2011 Apr; 26(4):1327-39. PubMed ID: 21148030
    [Abstract] [Full Text] [Related]

  • 33. Calcium-containing phosphate binder use associated with accelerated atherosclerotic coronary calcification.
    Paret CL.
    J Ren Nutr; 2003 Oct; 13(4):288-94. PubMed ID: 14566766
    [Abstract] [Full Text] [Related]

  • 34. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.
    Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P.
    Am Heart J; 2005 May; 149(5):820-5. PubMed ID: 15894962
    [Abstract] [Full Text] [Related]

  • 35. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.
    Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH, Sevelamer Study Group.
    J Am Soc Nephrol; 2008 Feb; 19(2):405-12. PubMed ID: 18199805
    [Abstract] [Full Text] [Related]

  • 36. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
    Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E.
    Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
    [Abstract] [Full Text] [Related]

  • 37. Mortality in kidney disease patients treated with phosphate binders: a randomized study.
    Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators.
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819
    [Abstract] [Full Text] [Related]

  • 38. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.
    Cancela AL, Oliveira RB, Graciolli FG, dos Reis LM, Barreto F, Barreto DV, Cuppari L, Jorgetti V, Carvalho AB, Canziani ME, Moysés RM.
    Nephron Clin Pract; 2011 Mar; 117(1):c74-82. PubMed ID: 20689328
    [Abstract] [Full Text] [Related]

  • 39. [Sevelamer:hydrochloride].
    Hyodo T, Taira T, Wakai H, Takemura T, Yamamoto S, Yashida K, Baba S.
    Clin Calcium; 2005 Jan; 15(1):61-70. PubMed ID: 15632474
    [Abstract] [Full Text] [Related]

  • 40. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, Kono T, Uchino J, Masaki K, Date T, Shigematsu T, Research Group for Future Hemodialysis.
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.